445264-60-8

Usage

Uses

Used in Chemical Synthesis:
3-METHOXY-5-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-PYRIDINE is used as an intermediate in the synthesis of various organic compounds, particularly for the preparation of complex molecules with potential applications in pharmaceuticals and materials science.
Used in Suzuki-Miyaura Aryl-Aryl Cross-Coupling:
In the field of organic chemistry, 3-METHOXY-5-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-PYRIDINE is used as a reagent for Suzuki-Miyaura aryl-aryl cross-coupling. This reaction is a powerful method for forming carbon-carbon bonds, which are essential in the construction of complex organic molecules and pharmaceutical compounds.
Used in the Synthesis of Anthracene-Based Bis-Pyridine Ligands:
In the field of coordination chemistry, 3-METHOXY-5-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-PYRIDINE is used as a starting material to synthesize anthracene-based bis-pyridine ligands (L). These ligands are employed in the preparation of fluorescent M2L4 type capsules, where M represents various metal ions such as Pt, Zn, Pd, Cu, Ni, Co, and Mn. These capsules have potential applications in sensing, imaging, and drug delivery.
Used in the Synthesis of Pyridylmethyl-Pyridine Derivatives:
3-METHOXY-5-(4,4,5,5-TETRAMETHYL-[1,3,2]DIOXABOROLAN-2-YL)-PYRIDINE is also used as a starting material in the synthesis of pyridylmethyl-pyridine derivatives. These derivatives have been identified as potent inhibitors of 11β-hydroxylase (CPY11B1), an enzyme involved in the biosynthesis of steroid hormones. Inhibiting this enzyme can have therapeutic implications in the treatment of various hormone-related disorders.

InChI:InChI=1/C12H18BNO3/c1-11(2)12(3,4)17-13(16-11)9-6-10(15-5)8-14-7-9/h6-8H,1-5H3

Upstream product

• 7295-76-3 3-methoxypyridine 
• 73183-34-3 bis(pinacol)diborane 
• 50720-12-2 3-bromo-5-methoxypyridine 
• 76-09-5 2,3-dimethyl-2,3-butane diol 
• 625-92-3 3,5-dibromopyridine 

Downstream Products

• 1025717-58-1 N-(3-(4-(5-methoxypyridin-3-yl)pyrimidin-2-ylamino)-4-methylphenyl)-1-ethyl-3-methyl-1H-pyrazole-5-carboxamide trifluoroacetate 
• 1246372-80-4 2-(3,4-dimethoxyphenyl)-5-(5-methoxypyridin-3-yl)imidazo[2,1-b][1,3,4]thiadiazole 
• 1352419-07-8 rac-5-[3-(5-methoxypyridin-3-yl)phenyl]-5-methylmorpholin-3-one 
• 1352419-66-9 rac-5-[3-(5-methoxypyridin-3-yl)phenyl]-5-trifluoromethylmorpholin-3-one 
• 1352415-46-3 rac-5-[3-(5-methoxypyridin-3-yl)phenyl]-5-methyl-5,6-dihydro-2H-1,4-oxazin-3-amine 
• 1352419-21-6 rac-6-[3-(5-methoxypyridin-3-yl)phenyl]-6-methyl-4-oxa-7-azaspiro[2.5]octan-8-one 
• 1392429-37-6 C₃₁H₃₆F₂N₆O₅S 
• 1401348-58-0 methyl 3-(5-methoxypyridin-3-yl)-1-tosyl-1H-pyrrolo[3,2-b]pyridine-5-carboxylate 
• 1033805-95-6 (S)-3-[4-(2-amino-6-{(S)-2,2,2-trifluoro-1-[4-(5-methoxypyridin-3-yl)phenyl]ethoxy}pyrimidin-4-yl)phenyl]-2-tert-butoxycarbonylaminopropionic acid 
• 1033805-90-1 (S)-3-[4-(2-amino-6-{2,2,2trifluoro-1-[2-fluoro-4-(5-methoxypyridin-3-yl)phenyl]ethoxy}pyrimidin-4-yl)phenyl]-2-tert-butoxycarbonylaminopropionic acid 
• 1352126-32-9 rac-5-amino-3-[3-(5-methoxypyridin-3-yl)phenyl]-1,3-dimethyl-3,6-dihydro-1H-pyrazin-2-one 

Relevant academic research and scientific papers

Enzyme-like Supramolecular Iridium Catalysis Enabling C?H Bond Borylation of Pyridines with meta-Selectivity

The use of secondary interactions between substrates and catalysts is a promising strategy to discover selective transition metal catalysts for atom-economy C?H bond functionalization. The most powerful catalysts are found via trial-and-error screening due to the low association constants between the substrate and the catalyst in which small stereo-electronic modifications within them can lead to very different reactivities. To circumvent these limitations and to increase the level of reactivity prediction in these important reactions, we report herein a supramolecular catalyst harnessing Zn???N interactions that binds to pyridine-like substrates as tight as it can be found in some enzymes. The distance and spatial geometry between the active site and the substrate binding site is ideal to target unprecedented meta-selective iridium-catalyzed C?H bond borylations with enzymatic Michaelis–Menten kinetics, besides unique substrate selectivity and dormant reactivity patterns.

Compound containing L-prolinamide fragment, and preparation method and application thereof

The invention discloses a compound containing an L-prolinamide fragment, and a preparation method and an application thereof and belongs to the technical field of antitumor drugs. The compound containing the L-prolinamide fragment comprises a 5-aryl pyrid

Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships

Cyclic nucleotide cAMP is a ubiquitous secondary messenger involved in a plethora of cellular responses to biological agents involving activation of adenylyl cyclase. Its intracellular levels are tightly controlled by a family of cyclic nucleotide degrading enzymes, the PDEs. In recent years, cyclic nucleotide phosphodiesterase type 4 (PDE4) has aroused scientific attention as a suitable target for anti-inflammatory therapy in respiratory diseases, particularly in the management of asthma and COPD. Here we describe our efforts to discover novel, highly potent inhaled inhibitors of PDE4. Through structure based design, with the inclusion of a variety of functional groups and physicochemical profiles in order to occupy the solvent-filled pocket of the PDE4 enzyme, we modified the structure of our oral PDE4 inhibitors to reach compounds down to picomolar enzymatic potencies while at the same time tackling successfully an uncovered selectivity issue with the adenosine receptors. In vitro potencies were demonstrated in a rat lung neutrophilia model by administration of a suspension with a Penn-Century MicroSprayer Aerosolizer.

INHIBITORS OF THE KYNURENINE PATHWAY

The present application provides novel inhibitors of indoleamine 2,3-dioxygenase-1 and/or indoleamine 2,3-dioxygenase-2 and/or tryptophan 2,3-dioxygenase, metabolites thereof, and phannaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. A therapeutically effective amount of one or more of the compounds of formula (I) is useful in treating diseases resulting from dysregulation of the kynurenine pathway. Compounds of formula (I) act by inhibiting the enzymatic activity or expression of indoleamine 2,3-dioxygenase-1 and/or indoleamine 2,3-dioxygenase-2 and/or tryptophan 2,3-dioxygenase.

Highly fluorescent M2L4 molecular capsules with anthracene shells

M2L4 molecular capsules self-assembled from M(ii) ions (where M = Zn, Ni, and Pd) and bent bidentate ligands constructed from anthracene fluorophores. The Ni(ii) and Zn(ii) capsules exhibited weak to strong blue emission unlike traditional Pd(ii) cages and capsules. The Royal Society of Chemistry 2011.

(3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors

New (3-oxo)pyridazin-4-ylurea derivatives having the chemcial structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of the phosphodiesterase IV (PDE4).

ANTIBACTERIAL CONDENSED THIAZOLES

Compound of formula (I) have antibacterial activity: wherein: m is 0 or 1; Q is hydrogen or cyclopropyl; AIk - is an optionally substituted, divalent C1-C6 alkylene, alkenylene or alkynylene radical which may contain an ether (-0-), thioether (-S-) or amino (-NR)- link, wherein R is hydrogen, -CN or C1-C3 alky!; X is -C(=O)NR6-, or -C(=O)O- wherein R6 is hydrogen, optionally substituted C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl; Z1 is -N= or -CH= Z2 is -N= or -C(R1)=; R1 is hydrogen, methyl, ethyl, ethenyl, ethynyl, methoxy, mercapto, mercaptomethyl halo, fully or partially fluorinated (C1-C2)alkyl, (C1-C2JaIkOXy or (C1-C2)alkylthio, nitro, or nitrile (-CN); R2 is a group Q1 -[Alk1]q-Q2 -, wherein q is 0 or 1; AIkl is an optionally substituted, divalent, straight chain or branched C1-C6 alkylene, or C2-C6 alkenylene or C2-C6 alkynylene radical which may contain or terminate in an ether (-O-), thioether (-S-) or amino (-NR)- link; Q2 is an optionally substituted divalent monocyclic carbocyclic or heterocyclic radical having 5 or 6 ring atoms or an optionally substituted divalent bicyclic carbocyclic or heterocyclic radical having 9 or 10 ring atoms; Q1 is hydrogen, an optional substituent or an optionally substituted carbocyclic or heterocyclic radical having 3-7 ring atoms